Hanmi Pharmaceutical's second-quarter performance improved. In the domestic market, self-developed new drug products have done well. Sales of Beijing Hanmi have more than doubled despite the sluggishness caused by COVID-19.

Hanmi announced on the 29th that its operating profit in the second quarter increased 49.6% year-on-year to ₩15.9 billion. Its sales increased 14.7% year-on-year to ₩279.3 billion, while its net profit expanded 43.1% to ₩8.3 billion.

Hanmi explained, "The stable prescription sales of self-developed products and the explosive growth of Chinese local Beijing pharmaceuticals caused strong sales." Rosuzet, Amosartan, and Esomzol are the reasons fo